Thursday, 5 November 2026European Markets

SMURFIT KAPPA GP And TFF GROUP Have A High Dividend Yield And Return On Equity In The Packaging & Containers Industry.

Loading stream...

(vianews) - smurfit kappa gp (sk3.ir) is among this list of stock assets with the highest dividend rate and return on equity on the packaging & containers industry.

financial asset price forward dividend yield return on equity
smurfit kappa gp (sk3.ir) €34.24 4.11% 20.04%
tff group (tff.pa) €39.30 1% 14.21%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. smurfit kappa gp (sk3.ir)

4.11% forward dividend yield and 20.04% return on equity

smurfit kappa group plc, together with its subsidiaries, manufactures, distributes, and sells containerboard, corrugated containers, and other paper-based packaging products in the americas and europe. the company offers e-commerce, retail, consumer, industrial, bottle, protective, heavy-duty, hexacomb, and various punnet packaging products; composite cardboard tubes, bags, and sacks; and bag-in-box, a packaging system that comprises films, accessories, bags, taps, and boxes. it also provides point of sale displays; cardboards of social distancing; corrugated sheet boards, solid board sheets, folding carton sheet boards, sack kraft papers, mg brown kraft papers, preprint products, agro-papers, technical papers, banabag, and catcher board mb12; various types of containerboards, such as kraftliners, testliners, and containerboard flutings; and solid board sheets. in addition, the company offers recycling solutions to cardboard and paper products; and supplies packaging machinery. it primarily serves consumer goods, industrial goods, and food and drink sectors. smurfit kappa group plc was founded in 1934 and is headquartered in dublin, ireland.

earnings per share

as for profitability, smurfit kappa gp has a trailing twelve months eps of €3.64.

pe ratio

smurfit kappa gp has a trailing twelve months price to earnings ratio of 9.41. meaning, the purchaser of the share is investing €9.41 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 20.04%.

more news about smurfit kappa gp.

2. tff group (tff.pa)

1% forward dividend yield and 14.21% return on equity

tff group manufactures and distributes barrels and wood products for the aging of wines, spirits, and alcohols in france, rest of europe, oceania and south africa, the united states, and internationally. the company also offers staves, cooperages, casks, wood and oenological products, and stainless steel containers. it primarily serves wine, whisky, and bourbon markets. the company was formerly known as tonnellerie françois frères. tff group was founded in 1910 and is based in saint-romain, france.

earnings per share

as for profitability, tff group has a trailing twelve months eps of €1.68.

pe ratio

tff group has a trailing twelve months price to earnings ratio of 23.39. meaning, the purchaser of the share is investing €23.39 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 14.21%.

yearly top and bottom value

tff group's stock is valued at €39.30 at 17:40 est, way below its 52-week high of €44.00 and way higher than its 52-week low of €30.40.

moving average

tff group's value is below its 50-day moving average of €40.90 and higher than its 200-day moving average of €38.42.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, tff group's stock is considered to be overbought (>=80).

more news about tff group.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Oncology Data Season and Biotech Capital Allocation: ESMO Readouts, Ivonescimab PDUFA, and Diverging Corporate Moves
Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,549 source documents archived
Query this data → isubstrate.com